米国の臨床化学分析装置市場 – 2031 年までの業界動向と予測

米国の臨床化学分析装置市場の分析と洞察

米国の臨床化学分析装置市場には、cobas、cobas integra など、さまざまなモデルの臨床化学分析装置があります。臨床化学分析装置は主に、糖尿病や心臓病など、さまざまな健康状態を示す検査を行うために使用されます。分析装置は、独立した研究所や病院に設置されています。臨床化学分析装置は、最短のターンアラウンド時間で正確な結果を提供し、通常は半自動または全自動です。

分析装置が迅速に結果を提供できることは、指摘された疾患の早期治療に役立ちます。臨床化学分析装置市場の成長に寄与する主な要因は、技術の進歩、慢性疾患の罹患率の増加、予防医療検査に関する意識の高まりです。しかし、化学分析装置に関連する高コストと熟練した人材の不足は、米国の臨床化学分析装置市場の成長の抑制要因となっています。

Data Bridge Market Researchは、米国の臨床化学分析装置市場は、2023年の54億ドルから2031年には72億ドルに達し、2024年から2031年の予測期間に3.9%のCAGRで成長すると分析しています。

市場の定義

臨床化学分析装置は、血液、尿、血清、血漿、脳脊髄液など、さまざまな種類のサンプルに対して幅広い生化学検査を実行するために使用される自動機器です。これらの分析装置により、医療従事者は電解質、酵素、ホルモン、タンパク質、脂質、代謝物などの物質の濃度を測定でき、病気の診断と監視、臓器機能の評価、全体的な健康状態の評価に貴重な情報を提供します。

これらの分析装置は、さまざまな研究室や病院などの臨床現場で使用されています。臨床化学分析装置の用途には、薬物乱用検査、心臓マーカー、代謝機能検査、糖尿病などの病状のモニタリングなどがあります。世界中の医療システムが予防医療、病気の早期発見、個別化医療を優先し、高度な診断技術とソリューションの需要が高まっているため、臨床化学分析装置市場は今後も成長を続けると予想されています。

米国の臨床化学分析装置市場の動向

このセクションでは、市場の推進要因、機会、制約、課題について理解します。これらについては、以下で詳しく説明します。      

ドライバ

• 慢性疾患の蔓延

慢性疾患の罹患率の上昇は、アルコールやタバコの過剰摂取など、不健康なライフスタイルに起因すると考えられます。また、上記の要因は肥満、高血圧、コレステロールなどの健康リスクも高め、慢性疾患の症例がかつてないほど増加することにつながっています。疾患の罹患率が上昇するにつれて、早期診断の需要も高まっています。

The chronic diseases such as diabetes, cardiovascular disorders, kidney diseases, and liver diseases often require regular monitoring and management. Clinical chemistry analyzers play a critical role in diagnosing these conditions, monitoring disease progression, and evaluating treatment effectiveness by measuring various biochemical parameters in bodily fluids such as blood and urine. These analyzers enable healthcare providers to perform comprehensive biochemical profiling, allowing for early detection of chronic diseases, assessment of organ function, and identification of risk factors. Early detection and proactive management of chronic diseases can help prevent complications, improve patient outcomes, and reduce healthcare costs.

Hence, the increasing prevalence of chronic diseases drives the demand for diagnostic testing, leading to the growth of the clinical chemistry analyzers market and therefore is acting as a driver for market growth.

Restraint

• High Cost Of Analyzer

The high cost of clinical chemistry analyzers can indeed be a significant barrier to their adoption and can restrain the growth of the market in several ways.

Limited Affordability: The healthcare facilities may find it challenging to afford the upfront capital investment required to purchase clinical chemistry analyzers. The high cost of acquisition can deter smaller clinics, and healthcare facilities with limited budgets from investing in these analyzers, thereby restricting their access to advanced diagnostic capabilities

Operational Expenses: In addition to the initial purchase cost, clinical chemistry analyzers often require ongoing maintenance, calibration, and consumables such as reagents and quality control materials. These operational expenses can further strain the budgets of healthcare facilities, particularly if they are already facing financial constraints. High operational costs may lead to reluctance in adopting or expanding the use of clinical chemistry analyzers.

The high cost of clinical chemistry analyzers can create barriers to entry for smaller manufacturers and startups, limiting competition in the market. As a result, there may be fewer options available to healthcare facilities, leading to less competitive pricing and slower innovation in the industry. This lack of competition can further contribute to the perception of clinical chemistry analyzers as expensive investments. Hence, the high prices of analyzers is expected to act as a restraint for the market growth.

Opportunity

• Rise in Preference for Preventive Health Check Ups

Preventive health check-ups are preventive actions performed for the initial detection of disease and safeguard against likely exposure to any disease in the future. The check-up is comprised of identification of disease and examinations of risk factors to limit loss at an early stage. Preventive health check-ups are performed with the help of various lab tests, including blood chemistry, hemoglobin, urinalysis, screening for prostate cancer, screening for ovarian cancer, ECG, lipid panel, and others.

Overall, the rising preference for preventive care creates a favorable market environment for clinical chemistry analyzers and other diagnostic technologies. As healthcare systems and consumers increasingly prioritize prevention and wellness, the demand for advanced diagnostic tools to support preventive care initiatives is expected to continue growing, and hence acting as an opportunity for the market growth.

Challenge

• Inaccurate Results of Tests

Patient safety emphasizes analyzing, reporting, and preventing medical errors, which often lead to adverse events and inappropriate clinical laboratory tests. Inappropriate clinical laboratory tests result in a greater chance of false-positive irregular outcomes, leading to serious consciousness.

Inaccurate results of tests are harmful financially and psychologically to the patients and to healthcare facilities which are decreasing authenticity, reliability and decreasing usage of clinical laboratory services due to these reason inaccurate results of tests is working as a challenge for the market.

Recent Developments

• In July 2023, F. Hoffmann-La Roche Ltd announced that it will showcase its latest product in the conference (American Association of Clinical Chemistry (AACC) Scientific Meeting). It includes featuring the newest innovations - the cobas 5800, which is a comapct, fully-automated molecular PCR-testing solution with a wide menu of assays. The product combine clinical chemistry, immunoassay and Ion-Selective Electrode (ISE) diagnostic testing on a single platform for low- to mid-volume testing needs. This has helped the company to make its unique position in the market
• In February 2024, Beckman Coulter, Inc. announced that it will launch new DxC 500 AU Chemistry Analyzer, an automated clinical chemistry analyzer, at Medlab Middle East in Dubai. The analyser is designed to address the complete needs of healthcare systems and has helped the company to expand its portfolio
• In July 2022, Thermo Fisher Scientific Inc. showcased its innovative diagnostic technologies, assays and a complement of solutions for researchers developing new diagnostics at 74th American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Laboratory Exposition (AACC 2022). This has helped the company to display its innovative products and new technologies in the market
• In August 2023, Abbott announced that it has received FDA clearance for its advanced Alinity h-series hematology system. It will help the laboratories run complete blood counts (CBC) as a part of Abbott’s Alinity family of diagnostic products. This has helped the company to increase its product offering

U.S. Clinical Chemistry Analyzer Market Scope

The U.S. clinical chemistry analyzer market is segmented into seven notable segments based on product type, test type, modality, application, specimen, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.

Product Type

• Reagents
• Instruments

On the basis of product type, the market is segmented into reagents and instruments.

Test Type

• Metabolic Panel (MP) 
• General Chemistry Test 
• Lipid Profile 
• Liver Panel 
• Electrolyte Panel 
• Renal Profile 
• Specialty Chemical Tests 
• Thyroid Function Panel 

On the basis of test type, the market is segmented into metabolic panel (MP), general chemistry test, lipid profile, liver panel, electrolyte panel, renal profile, specialty chemical tests, and thyroid function panel.

Modality

• Benchtop
• Portable
• Standalone
• Others

On the basis of modality, the market is segmented into benchtop, portable, standalone and others.

Application

• Inflammatory Diseases 
• Diabetes 
• Cardiovascular Diseases 
• Cancer 
• Abuse of Drugs 
• Renal Failure 
• Nutritional Deficiency 
• Others 

On the basis of application, the market is segmented into inflammatory diseases, diabetes, cardiovascular diseases, cancer, abuse of drugs, renal failure, nutritional deficiency and others.

Specimen

• Serum 
• Plasma 
• Urine 
• Cerebrospinal Fluid (CSF) 
• Blood
• Amniotic Fluid 
• Saliva
• Others 

On the basis of specimen, the market is segmented into serum, plasma, urine, cerebrospinal fluid (CSF), blood, amniotic fluid, saliva and others.

End User

• Hospitals
• Independent Diagnostic Laboratories (Laboratories Outside Hospitals) 

On the basis of end user, the market is segmented into hospitals and independent diagnostic laboratories (laboratories outside hospitals).

Distribution Channel

• Direct Tender
• Retail Sales
• Others

On the basis of distribution channel, the market is segmented into direct tender, retail sales and others.

U.S. Clinical Chemistry Analyzer Market Regional Analysis/Insights

The U.S. clinical chemistry analyzer market is categorized into seven notable segments which are based on the product type, test type, modality, application, specimen, end user and distribution channel.

U.S. clinical chemistry analyzer market is expected to grow due to presence of big major players in the market, increased development and research activities in healthcare sector. The region's early tech adoption and mature market contribute to a strong demand for advanced solutions.

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、国別データの予測分析を提供する際には、グローバル ブランドの存在と可用性、地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、販売チャネルの影響も考慮されます。

競争環境と米国の臨床化学分析装置の市場シェア分析

米国の臨床化学分析装置市場の競争状況は、競合他社の詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品の承認、製品の幅と広さ、アプリケーションの優位性、製品タイプのライフライン曲線が含まれます。上記のデータ ポイントは、会社の市場への重点にのみ関連しています。

市場で活動している主要な市場プレーヤーには、F. Hoffmann-La Roche Ltd、Beckman Coulter, Inc.（Danaherの子会社）、Thermo Fisher Scientific Inc.、Abbott、Shenzhen Mindray Bio-Medical Electronics Co., Ltd.、HORIBA、ELITech Group、Randox Laboratories Ltd.、Medica Corporation、JEOL Ltd.、TECO DIAGNOSTICS、FURUNO ELECTRIC CO.,LTD.、Hitachi High-Tech Corporationなどがあります。

SKU-59303